Particle.news
Drug Development Acquisitions Drug Pricing Biotechnology Manufacturing Vaccine Development Corporate Governance Drug Manufacturing Novo Nordisk Investment Companies Pfizer Mergers and Acquisitions AstraZeneca Drug Sales Drug Approval Corporate Transactions Eli Lilly Drug Manufacturers Research and Development Weight Loss Drugs Vaccines Pharmaceutical Companies Drug Companies Clinical Trials Market Trends Market Competition Biopharmaceuticals Stock Market GSK Competition Pharmaceutical Industry Corporate Strategy Regulations Product Development Opioid Crisis Company Performance Vaccine Manufacturing Regeneron Pharmaceuticals Vaccine Manufacturers Generic Drugs Partnerships AbbVie Investments Lawsuits Merck Amylyx Pharmaceuticals Drug Shortages Johnson & Johnson Market Analysis FDA Approval Supply Chain Management Drug Market Regulatory Compliance Bristol Myers Squibb Consumer Products Retail Pharmacy Corporate Acquisitions Opioids Regulatory Approval Infant Nutrition Corporate Actions Biosimilars Tariffs Drug Discovery Earnings Reports Competitors Sales Drug Regulation Product Safety Gene Therapy Market Revenue Animal Health Drug Safety Regulation Licensing Agreements Manufacturers Vertex Pharmaceuticals Investor Relations Drug Approvals Gene Therapy COVID-19 Vaccines Sanofi Emergency Contraception Sales Healthcare Sales Performance Big Pharma Corporate Operations Purdue Pharma Biotech Bayer Biopharmaceutical Companies Multinational Corporations Litigation Obesity Drugs Agriculture Nicotine Products Drugmakers Company Operations Sleep Aids
The company surpassed analyst expectations, reaffirmed 2025 guidance, and outlined strategies to mitigate tariff impacts while navigating mixed portfolio performance.
